Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 31, 2020 at 11:22 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,730
    Likes Received:
    3
    via Daiichi Sankyo announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma and related lymphomas.

    article source